Company intelligence / Profile preview

GlyCardial Diagnostics

Ownership: Private
Development stage: Other

Overview

GlyCardial Diagnostics has developed a proprietary in vitro diagnostic test based on the detection of glycosylated apolipoprotein J (Apo J-Glyc) in blood for early diagnosis of myocardial ischemia. The company completed patient recruitment for its pivotal EDICA trial across 10 hospitals in Spain and the UK, validating this novel biomarker. Results were presented at major cardiology congresses, and production batches have been manufactured under GMP-like conditions. The technology aims to enable earlier intervention before irreversible cardiac damage occurs.

Therapeutic areas: Cardiovascular
Modalities: Diagnostic device (in vitro diagnostic test)Antibody (as part of the biomarker assay)
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

iSCOR

Clinical Studies

Indications: Cardiac ischemia

Beyond the preview

Go deeper on GlyCardial Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlyCardial Diagnostics.

Explore the full profile